Anbiping's First-Half Non-Recurring Loss Narrows to 680,000 Yuan

Earnings
โดย 财中社·CN·Read original
Summary · why it matters

Anbiping released its 2026 half-year report. First-half operating revenue was 172 million yuan, up 7.6 percent year on year. Net profit attributable to the parent turned from loss to profit, reaching 760,000 yuan. The non-recurring net loss attributable to the parent narrowed to 680,000 yuan, compared with a loss of 14.71 million yuan in the same period last year. In the second quarter, the company's operating revenue was 91.96 million yuan, up 5.9 percent year on year. Net profit attributable to the parent turned positive at 2.6 million yuan, and non-recurring net profit attributable to the parent turned positive at 2.07 million yuan. As of the end of the second quarter, total assets were 1.25 billion yuan, down 2.9 percent from the end of the previous year, and net assets attributable to the parent were 1.137 billion yuan, down 4.0 percent. The company's main business covers the full industry chain of hospital pathology departments. It added 47 medical device registration certificates and 47 overseas certifications. Revenue from pathology department co-construction business was 14.06 million yuan, up 20.28 percent year on year.

Impact on stocks 1

Others▲ · 1 stocks
© 2026 MarketDXNews